2. Search Result
Search Result
Results for "

KCC

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

9

Recombinant Proteins

4

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-110110
    VU0463271

    		Potassium Channel Neurological Disease
    VU0463271 is a selective KCC2 antagonist, with an IC50 of 61 nM.
    VU0463271
  • HY-103023
    CLP290
    2 Publications Verification

    		 Potassium Channel Neurological Disease
    CLP290 is an orally available activator of the neuron-specific K +-Cl - cotransporter KCC2, displays potential for treatment of a wide range of neurological and psychiatric indications. CLP290 can significantly lower blood arginine-vasopressin (AVP) and glucose levels in STZ (HY-13753) rats .
    CLP290
  • HY-131031
    KCC-07
    1 Publications Verification

    		 DNA Alkylator/Crosslinker Cancer
    KCC-07 is a potent and brain-penetrant MBD2 (methyl-CpG-binding domain protein 2) inhibitor. KCC-07 prevents binding of MBD2 to methylated DNA and activates brain specific angiogenesis inhibitor 1 (BAI1) inducing anti-proliferative BAI1/p53/p21 signaling. Anticancer activity .
    KCC-07
  • HY-110143
    CLP257

    		Potassium Channel Neurological Disease
    CLP257 is a selective K +-Cl cotransporter KCC2 activator with an EC50 of 616 nM. CLP257 is inactive against NKCC1, GABAA receptors, KCC1, KCC3 or KCC4. CLP257 restores impaired Cl transport in neurons with diminished KCC2 activity. CLP257 alleviates hypersensitivity in rats with neuropathic pain. CLP257 modulates plasmalemmal KCC2 protein turnover post-translationally .
    CLP257
  • HY-16689
    VU 0240551
    1 Publications Verification

    		 Potassium Channel Others
    VU 0240551 is a potent neuronal K-Cl cotransporter KCC2 inhibitor (IC50=560 nM) and is selective versus NKCC1. VU 0240551 also inhibits hERG and L-type Ca 2+ channels. VU 0240551 attenuates GABA-induced hyperpolarization of P cells, produces a positive shift in the P cell GABA reversal potential and enhances P cell synaptic transmission .
    VU 0240551
  • HY-169929
    KCC2 potentiators-1

    		NKCC Neurological Disease
    KCC2 potentiators-1 (Compound 2) is a Potassium chloride cotransporter-2 (KCC2) potentiator. KCC2 potentiators-1 is promising for research of neurological disorder .
    KCC2 potentiators-1
  • HY-123290
    KCC009

    		Glutaminase Cancer
    KCC009, a transglutaminase 2 (TG2) inhibitor, induces p53-independent radiosensitization .
    KCC009
  • HY-18172
    KCC2 blocker 1

    		Potassium Channel Neurological Disease
    KCC2 blocker 1 is an orally active and selective K +-Cl - cotransporter KCC2 blocker with an IC50 of 1 μM. KCC2 blocker 1 is a benzyl prolinate .
    KCC2 blocker 1
  • HY-110110A
    VU0463271 quarterhydrate

    		Potassium Channel Neurological Disease
    VU0463271 quarterhydrate is a potent KCC2 antagonist, with an IC50 of 61 nM .
    VU0463271 quarterhydrate
  • HY-18172A
    (+)-KCC2 blocker 1

    		Potassium Channel Neurological Disease
    (+)-KCC2 blocker 1 is a selective K +-Cl - cotransporter KCC2 blocker with an IC50 of 0.4 μM. (+)-KCC2 blocker 1 is a benzyl prolinate and a enantiomer of KCC2 blocker 1 .
    (+)-KCC2 blocker 1
  • HY-160083
    KCC2 Modulator-3

    		Potassium Channel Neurological Disease
    KCC2 Modulator-3 (Example 54) is a KCC2 modulator with an EC50 of 0.253  μM. KCC2 Modulator-3 can be used for neurological disorders research, such as epilepsy, neuropathic pain and Rett's syndrme .
    KCC2 Modulator-3
  • HY-115606
    ML077

    		NKCC Endogenous Metabolite Neurological Disease
    ML007 is a selective antagonist targeting the neuron-specific potassium-chloride co-transporter 2 (KCC2) with an IC50 for KCC2 is 537 nM, while its inhibitory activity on KCC1 is extremely weak (IC50 > 50 μM). ML077 inhibits the chloride ion excretion function of KCC2, increasing the intracellular chloride ion concentration, thereby enhancing the depolarization mediated by chloride ion channels. ML007 can promote glucose-stimulated insulin secretion (GSIS) without relying on KATP channels. ML007 can be used to study the functions related to pain, epilepsy, and insulin secretion .
    ML077
  • HY-160081
    KCC2 Modulator-1

    		Potassium Channel Neurological Disease Cancer
    KCC2 Modulator-1 (Example 52) is a KCC2 modulator with an EC50 value of 0.146 μM. KCC2 Modulator-1 can be used for the research of KCC2 mediated diseases .
    KCC2 Modulator-1
  • HY-178362
    CAII/VII-IN-1

    		Carbonic Anhydrase NKCC mTOR Neurological Disease
    CAII/VII-IN-1 is an orally active hCA II (KI = 12.3 nM), and hCA VII (KI = 22.6 nM) inhibitor, showing no significant activity against hCA I. CAII/VII-IN-1 shows excellent neuroprotective activity in vivo Pilocarpine (HY-B0726A)-induced seizure model. CAII/VII-IN-1 can upregulate KCC2 and inhibit mTOR, exerting neuroprotective effects. CAII/VII-IN-1 does not show any significant neurotoxic effects or alterations in liver and kidney function. CAII/VII-IN-1 can be used for the study of epilepsy .
    CAII/VII-IN-1
  • HY-160082
    KCC2 Modulator-2

    		Potassium Channel Neurological Disease
    KCC2 Modulator-2 (example 53) is a KCC2 modulator with an EC50 of 0.215 μM. KCC2 Modulator-2 can be used in the study of neurological disorders .
    KCC2 Modulator-2
  • HY-172816
    Carbonic anhydrase inhibitor 32

    		Carbonic Anhydrase mTOR NKCC Neurological Disease
    Carbonic anhydrase inhibitor 32 (compound 5B) is an orally active and selective hCA (Carbonic anhydrase ) II/VII inhibitor with the Ki values of 6.3 nM, 10.1 nM and 681 nM for hCA II, hCA VII and hCA I,respectively. Carbonic anhydrase inhibitor 32 shows neuroprotective and anticonvulsant potential by reducing mTOR activation, and raising hippocampus KCC2 levels .
    Carbonic anhydrase inhibitor 32
  • HY-18172B
    (-)-KCC2 blocker 1

    		Potassium Channel Neurological Disease
    (-)-KCC2 blocker 1 is an enantiomer of KCC2 blocker 1 (HY-18172). KCC2 blocker 1 (compound 13) is an orally active and selective K +-Cl - cotransporter KCC2 blocker with an IC50 of 1 μM .
    (-)-KCC2 blocker 1
  • HY-103023R
    CLP290 (Standard)

    		Reference Standards Potassium Channel Neurological Disease
    CLP290 (Standard) is the analytical standard of CLP290 (HY-103023). This product is intended for research and analytical applications. CLP290 is an orally available activator of the neuron-specific K+-Cl- cotransporter KCC2, displays potential for treatment of a wide range of neurological and psychiatric indications. CLP290 can significantly lower blood arginine-vasopressin (AVP) and glucose levels in STZ (HY-13753) rats .
    CLP290 (Standard)
  • HY-180056
    CAII-IN-12

    		Carbonic Anhydrase NKCC mTOR Neurological Disease
    CAII-IN-12 (compound 6c) is a potent and selective carbonic anhydrase (CA) II and VII inhibitor (hCA II Ki = 47.8 nM, hCA VII Ki = 3.6 nM) with anti-epilepitic activity. CAII-IN-12 displays selectivity over hCA I (Ki = 370 nM). CAII-IN-12 exhibits potent anticonvulsant activity in both Pentylenetetrazol- and Pilocarpine (HY-B0726A)-induced seizure mouse models. CAII-IN-12 increases expression of KCC2 in the hippocampus, maintains neuronal integrity, and reduces mTOR activity. CAII-IN-12 can be used for epilepsy research .
    CAII-IN-12

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: